Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTSONASDAQ:EDAPNASDAQ:NXGLNASDAQ:VANI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTSOCytosorbents$1.07-1.8%$0.96$0.70▼$1.61$66.99M1.05147,820 shs23,276 shsEDAPEdap Tms$1.77-1.1%$1.80$1.26▼$5.46$66.18M0.0197,880 shs4,881 shsNXGLNEXGEL$2.21-7.5%$2.49$1.84▼$5.10$16.92M0.5269,546 shs48,567 shsVANIVivani Medical$1.19$1.08$0.91▼$2.09$70.50M2.93162,371 shs41,579 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTSOCytosorbents+2.83%+9.00%+25.27%+1.87%+21.25%EDAPEdap Tms+4.07%-1.10%-16.74%-23.18%-66.23%NXGLNEXGEL+5.75%+4.37%-12.13%-14.03%+7.17%VANIVivani Medical+1.71%+6.25%+15.53%+12.26%-26.99%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCTSOCytosorbents1.9397 of 5 stars3.52.00.00.02.70.00.6EDAPEdap Tms2.2802 of 5 stars3.23.00.00.02.21.70.6NXGLNEXGEL1.1549 of 5 stars0.05.00.00.01.52.50.0VANIVivani Medical3.0001 of 5 stars3.53.00.00.03.33.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTSOCytosorbents 3.00Buy$5.50414.02% UpsideEDAPEdap Tms 2.33Hold$8.50380.23% UpsideNXGLNEXGEL 0.00N/AN/AN/AVANIVivani Medical 3.00Buy$4.00236.13% UpsideCurrent Analyst Ratings BreakdownLatest NXGL, VANI, CTSO, and EDAP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025VANIVivani MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.005/15/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.005/15/2025CTSOCytosorbentsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$1.00 ➝ $1.005/15/2025EDAPEdap TmsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral5/2/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/16/2025VANIVivani MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.004/4/2025EDAPEdap TmsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$8.00 ➝ $2.004/4/2025VANIVivani MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.004/3/2025CTSOCytosorbentsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$1.00 ➝ $1.004/1/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/28/2025EDAPEdap TmsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$5.00 ➝ $4.50(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTSOCytosorbents$35.33M1.90N/AN/A$0.52 per share2.06EDAPEdap Tms$62.77M1.05N/AN/A$1.66 per share1.07NXGLNEXGEL$10.23M1.65N/AN/A$0.90 per share2.46VANIVivani MedicalN/AN/AN/AN/A$0.41 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTSOCytosorbents-$28.51M-$0.28N/AN/AN/A-49.47%-118.54%-42.31%8/12/2025 (Estimated)EDAPEdap Tms-$22.92M-$0.62N/AN/AN/A-34.92%-44.21%-25.88%8/27/2025 (Estimated)NXGLNEXGEL-$3.16M-$0.45N/A∞N/A-52.60%-71.19%-34.79%N/AVANIVivani Medical-$25.65M-$0.43N/AN/AN/AN/A-102.42%-49.21%8/12/2025 (Estimated)Latest NXGL, VANI, CTSO, and EDAP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025EDAPEdap Tms-$0.16-$0.20-$0.04-$0.20$16.56 million$16.37 million5/14/2025Q1 2025CTSOCytosorbents-$0.08-$0.06+$0.02-$0.02$9.01 million$8.73 million5/13/2025Q1 2025NXGLNEXGEL-$0.10-$0.09+$0.01-$0.09$2.73 million$2.81 million5/13/2025Q1 2025VANIVivani Medical-$0.10-$0.11-$0.01-$0.11N/AN/A3/31/2025Q4 2024CTSOCytosorbents-$0.07-$0.03+$0.04-$0.14$10.09 million$9.20 million3/31/2025Q4 2024VANIVivani Medical-$0.10-$0.11-$0.01-$0.11N/AN/A3/27/2025Q4 2024EDAPEdap Tms-$0.11-$0.05+$0.06-$0.05$20.83 million$22.69 million3/24/2025Q4 2024NXGLNEXGEL-$0.10-$0.08+$0.02-$0.11$2.99 million$3.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTSOCytosorbentsN/AN/AN/AN/AN/AEDAPEdap TmsN/AN/AN/AN/AN/ANXGLNEXGELN/AN/AN/AN/AN/AVANIVivani MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTSOCytosorbents1.061.971.58EDAPEdap Tms0.082.181.46NXGLNEXGEL0.191.510.93VANIVivani MedicalN/A3.413.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTSOCytosorbents32.87%EDAPEdap Tms62.74%NXGLNEXGEL2.21%VANIVivani Medical6.78%Insider OwnershipCompanyInsider OwnershipCTSOCytosorbents6.60%EDAPEdap Tms0.23%NXGLNEXGEL20.55%VANIVivani Medical46.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTSOCytosorbents22062.61 million51.07 millionOptionableEDAPEdap Tms23037.39 million37.02 millionOptionableNXGLNEXGEL107.66 million5.10 millionNot OptionableVANIVivani Medical2059.24 million32.99 millionOptionableNXGL, VANI, CTSO, and EDAP HeadlinesRecent News About These CompaniesVivani Medical Appoints Anthony Baldor as Chief Financial OfficerJune 11 at 7:44 PM | manilatimes.netVivani Medical to Present at the 2025 BIO International ConventionJune 11 at 4:14 AM | finance.yahoo.comVivani Stock Gains After Announcing Spin-Off Plans for Cortigent UnitJune 2, 2025 | zacks.comCompanies To Watch: Vivani MedicalMay 30, 2025 | lifescienceleader.comVivani files with SEC to spin off neurostim business, focus on drug delivery implantsMay 29, 2025 | massdevice.comVivani Medical Announces Filing of Form 10 Registration Statement for Planned Spin-Off of Cortigent Neurostimulation Business to Vivani ShareholdersMay 29, 2025 | finance.yahoo.comHC Wainwright Estimates Vivani Medical Q1 EarningsMay 24, 2025 | marketbeat.comVivani Medical (NASDAQ:VANI) Receives Buy Rating from HC WainwrightMay 21, 2025 | marketbeat.comVivani Medical Reports Q1 2025 Results and Strategic UpdatesMay 20, 2025 | tipranks.comVivani Medical, Inc.: Vivani Medical Provides Business Update Including $3M Equity Financing and Reports First Quarter 2025 Financial ResultsMay 15, 2025 | finanznachrichten.deVivani Medical, Inc. Reports Successful Initial Data from LIBERATE-1™ Study and Secures $3M in Equity FinancingMay 13, 2025 | quiverquant.comVivani Medical Provides Business Update Including $3M Equity Financing and Reports First Quarter 2025 Financial ResultsMay 13, 2025 | globenewswire.comVivani Medical CEO to Present on Innovative Drug Delivery Solutions at AAPS Virtual WorkshopMay 9, 2025 | nasdaq.comVivani Medical to Present at the American Association of Pharmaceutical Scientists' “Beyond GLP1s: Where the Science will Take Business Next” Virtual WorkshopMay 7, 2025 | globenewswire.comVivani Medical to Participate in Virtual Fireside Chat Hosted by H.C. Wainwright & CompanyApril 16, 2025 | finance.yahoo.comVivani Medical, Okava expand collaboration to develop OKV-119 for dogsApril 16, 2025 | markets.businessinsider.comVivani Medical and Okava Expand Collaboration to Develop OKV-119 for Dogs, Targeting Metabolic Health and LongevityApril 15, 2025 | globenewswire.comGregg Williams Purchases 18,529 Shares of Vivani Medical, Inc. (NASDAQ:VANI) StockApril 12, 2025 | insidertrades.comVivani Medical, Inc. (NASDAQ:VANI) Director Purchases $33,660.00 in StockApril 9, 2025 | insidertrades.comWeight loss implants to increase compliance and cut admin burden for patientsApril 3, 2025 | finance.yahoo.comVivani Medical Reports 2024 Financial Results and Business ProgressApril 1, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNXGL, VANI, CTSO, and EDAP Company DescriptionsCytosorbents NASDAQ:CTSO$1.07 -0.02 (-1.83%) As of 04:00 PM EasternCytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.Edap Tms NASDAQ:EDAP$1.77 -0.02 (-1.12%) As of 03:59 PM EasternEDAP TMS SA is a holding company, which, through its subsidiary, engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. It operates through the High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) segments. The HIFU segment develops, manufactures, and markets devices for the minimally invasive ablation of certain types of localized tumors using HIFU technology. The UDS segment focuses on the development, marketing, manufacturing, and servicing of medical devices for the minimally invasive diagnosis or treatment of urological disorders, mainly urinary stones, and other clinical indications. The company was founded on December 3, 1979 and is headquartered in Vaulx-en-Velin, France.NEXGEL NASDAQ:NXGL$2.21 -0.18 (-7.53%) As of 03:59 PM EasternNEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. The company was incorporated in 2009 and is based in Langhorne, Pennsylvania.Vivani Medical NASDAQ:VANI$1.19 0.00 (0.00%) As of 04:00 PM EasternVivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ignore the Noise—Samsara Stock Is Still a Strong Buy Oracle’s Cloud Boom Is Just Getting Started Netflix Sets New Highs—Price Targets Keep Climbing IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA Alibaba’s Dip Is a Gift—Here’s the Price That Matters Betting on Disruption: Is Lemonade the Future of Insurance? Starbucks Stock: Culture Fix May Be Key to Long-Term Growth GameStop Turns a Profit, But Core Business Keeps Shrinking Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
